Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04797130
Other study ID # NL75126.068.20
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 23, 2021
Est. completion date January 27, 2022

Study information

Verified date September 2022
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to investigate if using Hospital Fit 2.0 as part of the usual care physiotherapy treatment of patients hospitalised at the department of Internal Medicine and the department of Pulmonology in MUMC+ will result in an increase in the amount of PA performed compared to patients who do not use Hospital Fit 2.0 as part of the physiotherapy treatment.


Description:

Rationale: Low physical activity (PA) levels are common in hospitalised patients. Digital health tools could be valuable to prevent negative effects of inactivity. We therefore developed Hospital Fit 1.0; a smartphone application with accelerometer, designed for hospitalised patients. It enables objective activity monitoring, provides patients insight in their recovery progress and offers a tailored exercise program. Hospital Fit 1.0 has recently been updated, resulting in the improved Hospital Fit 2.0. Improvements in the accelerometer algorithm are made, a goalsetting and reminder function are added, and data from the app can be linked to the electronic medical record. It is hypothesized that using Hospital Fit 2.0 as part of the physiotherapy treatment of hospitalised patients will result in an increase in the amount of PA performed compared to patients who do not use Hospital Fit 2.0 as part of the physiotherapy treatment. Objective: To investigate if using Hospital Fit 2.0 as part of the usual care physiotherapy treatment will result in an increase in the amount of PA performed compared to patients who did not use Hospital Fit 2.0 as part of the usual care physiotherapy treatment. Study design: Assessor blinded randomised controlled trial. Study population: 78 patients hospitalised equally distributed over the department of Internal Medicine and the department of Pulmonology at the Maastricht University Medical Center. Intervention (if applicable): PA will be measured with an accelerometer until discharge with a maximum of seven days in all patients. The control group receives usual care physiotherapy (n=39), while the intervention group uses Hospital Fit additionally (n=39). Main study parameters/endpoints: Primary outcome parameter: time spent walking per day (min). Secondary outcome parameters: time spent standing per day (min.), average time spent standing and walking (min.) measured over total measurement time (max. 7 days), number of transitions per day and average number of transitions measured over total measurement time (max. 7 days), number of times walking longer than 5 minutes per day and the average number measured over total measurement time (max.7 days), number of times sitting/lying longer than 30 minutes per day and the average number measured over total measurement time (max. 7 days) and the mILAS score per day (max. 7 days). Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The burden and risks on patients are minimal. The control group will receive usual care physiotherapy and will wear an accelerometer. The intervention group will use Hospital Fit 2.0 additionally. Wearing a small accelerometer and using Hospital Fit 2.0 should not be a burden to patients. The only burden is the time it take to prepare subjects (install app, explain study). No invasive interventions will take place.


Recruitment information / eligibility

Status Completed
Enrollment 78
Est. completion date January 27, 2022
Est. primary completion date January 27, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Aged between 18 and 75 years - Receiving physiotherapy while hospitalised at the department of Internal Medicine department or the department of Pulmonology at the Maastricht University Medical Centre (MUMC+) - Sufficient understanding of the Dutch language - Having access to a smartphone - Able to walk independently 2 weeks before admission, as scored on the Functional Ambulation Categories (FAC >3) Exclusion Criteria: - A contraindication to walking (as reported by the attending medical specialists in the medical record) - A contraindication to wearing an accelerometer, fixed by a hypoallergenic plaster at the upper leg (such as active bilateral upper leg infection, severe edema or bilateral transfemoral amputation) - Admission at the intensive care department - Impaired cognition (delirium / dementia) as reported by the attending doctor - Incapacitated subjects as reported by the attending medical specialist in the medical record. When any doubt arises, the patient will not be considered eligible - A life expectancy shorter than 3 months as mentioned by the attending medical specialist in the medical record - Previous participation in this study

Study Design


Intervention

Device:
Hospital Fit 2.0
HF consists of a smartphone app combined to an accelerometer. HF provides patients and physiotherapists direct feedback on patients' physical activity behavior.. Individual goals regarding the number of minutes per day spent walking can be set by the therapist. HF also shows patients insight into their own recovery progress. During every treatment, the physiotherapist will evaluate the extent of functional recovery. In addition, Hospital Fit will give physiotherapists the option of creating a patient-specific exercise program supported by videos. During every treatment session, the patient and physiotherapist will evaluate (and if necessary adapt) the amount of activity performed since the previous treatment, the extent of functional recovery and the exercise program.

Locations

Country Name City State
Netherlands MaastrichtUMC Maastricht Limburg

Sponsors (1)

Lead Sponsor Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time spent walking per day (min.) Defined as the total number of minutes walking per day. Period between inclusion and discharge, with a maximum of seven days
Secondary Average time spent walking Defined as the total number of minutes walking divided by the total number of valid measurement days in the period between inclusion and discharge, with a maximum of seven days Period between inclusion and discharge, with a maximum of seven days
Secondary Time spent standing per day (min.) Defined as the total number of minutes walking per day. Period between inclusion and discharge, with a maximum of seven days
Secondary Average time spent standing Defined as the total number of minutes standing divided by the total number of valid measurement days in the period between inclusion and discharge, with a maximum of seven days Period between inclusion and discharge, with a maximum of seven days
Secondary Number of transitions from a sedentary position (lying or sitting) to an active position (standing or walking) per day Defined as the total number of transitions from being sedentary (lying or sitting) to being physically active (standing or walking) per day Period between inclusion and discharge, with a maximum of seven days
Secondary Average number of transitions from a sedentary position (lying or sitting) to an active position (standing or walking) defined as the total number of transitions divided by the total number of valid measurement days in the period between inclusion and discharge with a maximum of seven days Period between inclusion and discharge, with a maximum of seven days
Secondary Number of times walking longer than five minutes Defined as the total number of times per day a patient spent walking for more than 5 minutes continuously without being interrupted by a standing or sedentary activity Period between inclusion and discharge, with a maximum of seven days
Secondary Average number of times walking longer than 5 minutes Defined as the total number of times per day a patient spent walking for more than 5 minutes continuously without being interrupted by a standing or sedentary activity, divided by the total number of valid measurement days in the period between inclusion and discharge, with a maximum of seven days Period between inclusion and discharge, with a maximum of seven days
Secondary Number of times sitting/lying longer than 30 minutes Defined as the total numer of times per day a patient spent more than 30 minutes lying and/or sitting without interrupting this behavior with a standing or walking activity. Period between inclusion and discharge, with a maximum of seven days
Secondary Average number of times sitting/lying longer than 30 minutes Defined as the total numer of times per day a patient spent more than 30 minutes lying and/or sitting without interrupting this behavior with a standing or walking activity, divided by the total number of valid measurement days in the period between inclusion and discharge, with a maximum of seven days Period between inclusion and discharge, with a maximum of seven days
Secondary mILAS score per day Defined as the modified Iowa Level of Assistance Score per day Period between inclusion and discharge, with a maximum of seven days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Active, not recruiting NCT02504697 - DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
Completed NCT01443845 - Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Phase 4
Terminated NCT00524095 - Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis Phase 2
Completed NCT00210249 - Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Completed NCT00023114 - p450 Mediated Lung Toxicity N/A
Recruiting NCT06056882 - Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules
Completed NCT03994848 - Incentive Spirometry Prehabilitation Study N/A
Completed NCT00366509 - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Withdrawn NCT05100160 - Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial) Phase 3
Completed NCT03229473 - Fall Risk Assessment in COPD
Recruiting NCT04767074 - A Non-pharmacological Cough Control Therapy N/A
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT04996693 - On Dose Efficiency of Modern CT-scanners in Chest Scans N/A
Recruiting NCT04996173 - Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis) N/A
Completed NCT04601545 - The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method N/A
Recruiting NCT03937583 - Screening for Cancer in Patients With Unprovoked VTE Phase 4
Recruiting NCT02862418 - Imaging of Lungs With a New Type of Magnetic Resonance Imaging (MRI) Called UTE (Ultrashort Echo Time)